Lipid- and polymer-based nanostructures for cancer theranostics

Theranostics

Volumn 2, Issue 12, 2012, Pages 1117-1126

  Luk, Brian T ^a   Fang, Ronnie H ^a   Zhang, Liangfang ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Fluorescence imaging; Liposomes; Magnetic resonance imaging; Nanotheranostics; Polymeric nanoparticles; Radionuclide imaging

Indexed keywords

1,6 HEXANEDIAMINE; CHITOSAN; CHLORIN E6; COPPER 64; CYCLODEXTRIN; DOXORUBICIN; FLUORESCENT DYE; GADOLINIUM; GADOLINIUM PENTETATE; LIPOSOME; MANGANESE; NANOMATERIAL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PHOTOSENSITIZING AGENT; POLOXAMER; POLYGLUTAMIC ACID; POLYMER; RADIOISOTOPE; RHENIUM 186; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TETRAXETAN; UNCLASSIFIED DRUG;

CANCER CELL; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER THERANOSTICS; CANCER THERAPY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; FLUORESCENCE; HUMAN; LEWIS CARCINOMA; LUNG CANCER; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SCINTISCANNING;

FLUORESCENCE IMAGING; LIPOSOMES; MAGNETIC RESONANCE IMAGING; NANOTHERANOSTICS; POLYMERIC NANOPARTICLES; RADIONUCLIDE IMAGING;

ANIMALS; HUMANS; LIPIDS; LIPOSOMES; NANOSTRUCTURES; NEOPLASMS; POLYMERS;

EID: 84870549579     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4381     Document Type: Review

References (79)

1. Morgan B. Opportunities and pitfalls of cancer imaging in clinical trials. Nat Rev Clin Oncol. 2011; 8: 517-27.
2. Sumer B, Gao JM. Theranostic nanomedicine for cancer. Nanomedicine. 2008; 3: 137-40.
3. Kievit FM, Zhang M. Cancer nanotheranostics: Improving imaging and therapy by targeted delivery across biological barriers. Adv Mater. 2011; 23: H217-H47.
4. Sun D. Nanotheranostics: Integration of imaging and targeted drug delivery. Mol Pharm. 2010; 7: 1879.
5. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7: 771-82.
6. Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: Current concepts and future directions. Mol Pharm. 2010; 7: 1899-912.
7. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008; 7: 591-607.
8. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7: 771-82.
9. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010; 9: 615-27.
10. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Ann Rev Med. 2012; 63: 185-98.
11. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009; 3: 16-20.
12. Timko BP, Whitehead K, Gao W, Kohane DS, Farokhzad O, Anderson D, et al. Advances in drug delivery. Ann. Rev. Mater. Res. 2011; 41: 1-20.
13. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m(2). Ann Oncol. 2000; 11: 1029-33.
14. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anti-Cancer Drug. 2005; 16: 691-707.
15. Ning YM, He K, Dagher R, Sridhara R, Farrell AT, Justice R, et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park). 2007; 21: 1503-8.
16. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharm Ther. 2008; 83: 761-9.
17. Na HB, Song IC, Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv Mater. 2009; 21: 2133-48.
18. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2: 683-93.
19. Kobayashi H, Ogawa M, Alford R, Choyke PL, Urano Y. New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev. 2010; 110: 2620-40.
20. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Comm. 2008; 29: 193-207.
21. Kelkar SS, Reineke TM. Theranostics: Combining imaging and therapy. Bioconj Chem. 2011; 22: 1879-903.
22. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009; 30: 592-9.
23. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5: 161-71.
24. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2: 751-60.
25. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997; 154: 123-40.
26. Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface. 2001; 6: 66-77.
27. Martina MS, Fortin JP, Menager C, Clement O, Barratt G, Grabielle-Madelmont C, et al. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J Am Chem Soc. 2005; 127: 10676-85.
28. Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP. MRI detection of single particles for cellular imaging. Proc Natl Acad Sci USA. 2004; 101: 10901-6.
29. Wang YXJ, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001; 11: 2319-31.
30. Kabalka GW, Davis MA, Moss TH, Buonocore E, Hubner K, Holmberg E, et al. Gadolinium-labeled liposomes containing various amphiphilic Gd-Dtpa derivatives -targeted MRI contrast enhancement agents for the liver. Magnet Reson Med. 1991; 19: 406-15.
31. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, et al. In vivo monitoring of tissue pharmacokinetics of liposome/ drug using MRI: Illustration of targeted delivery. Magnet Reson Med. 2004; 51: 1153-62.
32. Erten A, Wrasidlo W, Scadeng M, Esener S, Hoffman RM, Bouvet M, et al. Magnetic resonance and fluorescence imaging of doxorubicin-loaded nanoparticles using a novel in vivo model. Nanomedicine. 2010; 6: 797-807.
33. Tai LA, Tsai PJ, Wang YC, Wang YJ, Lo LW, Yang CS. Thermosensitive liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology. 2009; 20: 135101.
34. Tagami T, Foltz WD, Ernsting MJ, Lee CM, Tannock IF, May JP, et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials. 2011; 32: 6570-8.
35. Kono K, Nakashima S, Kokuryo D, Aoki I, Shimomoto H, Aoshima S, et al. Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy. Biomaterials. 2011; 32: 1387-95.
36. Soundararajan A, Bao A, Phillips WT, Perez R, Goins BA. [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol. 2009; 36: 515-24.
37. Bao A, Goins B, Klipper R, Negrete G, Phillips WT. Re-186-liposome labeling using Re-186-SNS/S complexes: In vitro stability, imaging, and biodistribution in rats. J Nucl Med. 2003; 44: 1992-9.
38. Bao A, Phillips W, Goins B, Otto R. Tumor brachytherapy using intratumoral injection of beta-emitting therapeutic radionuclides carried within nanoparticles. Med Phys. 2006; 33: 2236-7.
39. Chen LC, Chang CH, Yu CY, Chang YJ, Wu YH, Lee WC, et al. Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol. 2008; 35: 883-93.
40. Osborne MP, Richardson VJ, Jeyasingh K, Ryman BE. Radionuclide-labeled liposomes -a new lymph node imaging agent. Int J Nucl Med Biol. 1979; 6: 75-83.
41. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled PEGylated liposomes. Clin Cancer Res. 2001; 7: 243-54.
42. Hoefnagel CA. Radionuclide cancer therapy. Ann Nucl Med. 1998; 12: 61-70.
43. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol. 1996; 41: 1905-14.
44. Kostarelos K, Emfietzoglou D. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: Toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer Res. 2000; 20: 3339-45.
45. Kostarelos K, Emfietzoglou D, Stamatelou M. Liposome-mediated delivery of radionuclides to tumor models for cancer radiotherapy: A quantitative analysis. J Liposome Res. 1999; 9: 407-24.
46. Petersen AL, Binderup T, Rasmussen P, Henriksen JR, Elema DR, Kjaer A, et al. (64)Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials. 2011; 32: 2334-41.
47. Erdogan S, Roby A, Torchilin VP. Enhanced tumor visualization by gamma-scintigraphy with (111)In-labeled polychelating-polymer-containing immunoliposomes. Mol Pharma. 2006; 3: 525-30.
48. Mulder WJM, Strijkers GJ, Habets JW, Bleeker EJW, van der Schaft DWJ, Storm G, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. Faseb J. 2005; 19: 2008-10.
49. Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol. 2005; 196: 381-9.
50. Weissleder R, Tung CH, Mahmood U, Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999; 17: 375-8.
51. Lowery A, Onishko H, Hallahan DE, Han ZZ. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J Control Release. 2011; 150: 117-24.
52. Tian B, Al-Jamal WT, Al-Jamal KT, Kostarelos K. Doxorubicin-loaded lipid-quantum dot hybrids: Surface topography and release properties. Int J Pharm. 2011; 416: 443-7.
53. All-Jamal WT, Al-Jamal KT, Tian B, Cakebread A, Halket JM, Kostarelos K. Tumor targeting of functionalized quantum dot-liposome hybrids by intravenous administration. Mol Pharma. 2009; 6: 520-30.
54. Fang RH, Zhang L. Dispersion-based methods for the engineering and manufacture of polymeric nanoparticles for drug delivery applications. J Nanoeng Nanomanuf. 2011; 1: 106-12.
55. Aryal S, Hu CMJ, Zhang LF. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm. 2011; 8: 1401-7.
56. Liu ZH, Jiao YP, Wang YF, Zhou CR, Zhang ZY. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliver Rev. 2008; 60: 1650-62.
57. Hu KL, Li JW, Shen YH, Lu W, Gao XL, Zhang QZ, et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J Control Release. 2009; 134: 55-61.
58. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007; 28: 869-76.
59. Kabanov AV, Chekhonin VP, Alakhov VY, Batrakova EV, Lebedev AS, Meliknubarov NS, et al. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles -micelles as microcontainers for drug targeting. Febs Lett. 1989; 258: 343-5.
60. Miller DW, Batrakova EV, Waltner TO, Alakhov VY, Kabanov AV. Interactions of pluronic block copolymers with brain microvessel endothelial cells: Evidence of two potential pathways for drug absorption. Bioconjugate Chem. 1997; 8: 649-57.
61. Nitin N, LaConte LEW, Zurkiya O, Hu X, Bao G. Functionalization and peptide-based delivery of magnetic nanoparticles as an intracellular MRI contrast agent. J Biol Inorg Chem. 2004; 9: 706-12.
62. Andre JP, Toth E, Fischer H, Seelig A, Macke HR, Merbach AE. High relaxivity for monomeric Gd(DOTA)-based MRI contrast agents, thanks to micellar self-organization. Chem-Eur J. 1999; 5: 2977-83.
63. Zhang GD, Zhang R, Wen XX, Li L, Li C. Micelles based on biodegradable poly(L-glutamic acid)-b-polylactide with paramagnetic gd ions chelated to the shell layer as a potential nanoscale IVIRI-visible delivery system. Biomacromol. 2008; 9: 36-42.
64. Nasongkla N, Bey E, Ren JM, Ai H, Khemtong C, Guthi JS, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006; 6: 2427-30.
65. Guthi JS, Yang SG, Huang G, Li SZ, Khemtong C, Kessinger CW, et al. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol Pharm. 2010; 7: 32-40.
66. Lai JR, Chang YW, Yen HC, Yuan NY, Liao MY, Hsu CY, et al. Multifunctional doxorubicin/superparamagnetic iron oxide-encapsulated Pluronic F127 micelles used for chemotherapy/magnetic resonance imaging. J Appl Phys. 2010; 107: 09B318.
67. Ye FR, Ke TY, Jeong EK, Wang XL, Sung YG, Johnson M, et al. Noninvasive visualization of in vivo drug delivery of poly(L-glutamic acid) using contrast-enhanced MRI. Mol Pharmaceut. 2006; 3: 507-15.
68. Liu T, Li X, Qian Y, Hu X, Liu S. Multifunctional pH-Disintegrable micellar nanoparticles of asymmetrically functionalized beta-cyclodextrin-Based star copolymer covalently conjugated with doxorubicin and DOTA-Gd moieties. Biomaterials. 2012; 33: 2521-31.
69. Lu Z-R. Molecular imaging of HPMA copolymers: Visualizing drug delivery in cell, mouse and man. Adv Drug Deliver Rev. 2010; 62: 246-57.
70. Welch MJ, Hawker CJ, Wooley KL. The Advantages of Nanoparticles for PET. J Nucl Med. 2009; 50: 1743-6.
71. Chen XY, Hou YP, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, et al. Pegylated Arg-Gly-Asp peptide: Cu-64 labeling and PET imaging of brain tumor alpha(v)beta(3)-integrin expression. J Nucl Med. 2004; 45: 1776-83.
72. Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, et al. cRGD-functionalized, DOX-conjugated, and (64)Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials. 2011; 32: 4151-60.
73. Peng CL, Shih YH, Lee PC, Hsieh TMH, Luo TY, Shieh MJ. Multimodal image-guided photothermal therapy mediated by (188)Re-labeled micelles containing a cyanine-type photosensitizer. ACS Nano. 2011; 5: 5594-607.
74. Lee SJ, Koo H, Jeong H, Huh MS, Choi Y, Jeong SY, et al. Comparative study of photosensitizer loaded and conjugated glycol chitosan nanoparticles for cancer therapy. J Control Release. 2011; 152: 21-9.
75. Tsai H-C, Tsai C-H, Lin S-Y, Jhang C-R, Chiang Y-S, Hsiue G-H. Stimulated release of photosensitizers from graft and diblock micelles for photodynamic therapy. Biomaterials. 2012; 33: 1827-37.
76. Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed. 2008; 47: 7284-8.
77. Lobatto ME, Fuster V, Fayad ZA, Mulder WJM. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov. 2011; 10: 835-52.
78. Chan JM, Rhee J-W, Drum CL, Bronson RT, Golomb G, Langer R, et al. In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci USA. 2011; 108: 19347-52.
79. Dvir T, Timko BP, Kohane DS, Langer R. Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol. 2011; 6: 13-22.